|
| 36264007 | A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions. | Br J Haematol | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 36264007 | A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions. | Br J Haematol | 2023 |
| 36794595 | 'A novel approach for characterisation of KSHV-associated multicentric Castleman disease from effusions': Response. | Br J Haematol | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 36794595 | 'A novel approach for characterisation of KSHV-associated multicentric Castleman disease from effusions': Response. | Br J Haematol | 2023 |
| 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | J Clin Oncol | 2022 |
| 35534047 | Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. | J Immunother Cancer | 2022 |
| 34920453 | Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. | Blood Adv | 2022 |
| 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | J Clin Oncol | 2022 |
| 35534047 | Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. | J Immunother Cancer | 2022 |
| 34920453 | Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. | Blood Adv | 2022 |
| 32830879 | ICCS Women in Cytometry-Impact 10â¿¿years later: A call to promote gender equity. | Cytometry B Clin Cytom | 2021 |
| 33734005 | Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. | Leuk Lymphoma | 2021 |
| 33764809 | Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. | J Clin Oncol | 2021 |
| 33653216 | Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. | Leuk Lymphoma | 2021 |
| 33554406 | Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. | Oncologist | 2021 |
| 33211080 | Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. | JAMA Oncol | 2021 |
| 33273183 | Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. | AIDS | 2021 |
| 32830879 | ICCS Women in Cytometry-Impact 10â¿¿years later: A call to promote gender equity. | Cytometry B Clin Cytom | 2021 |
| 34607348 | Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. | Blood Adv | 2021 |
| 34529025 | Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. | JAMA Oncol | 2021 |
| 34525183 | Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. | Blood | 2021 |
| 33653216 | Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. | Leuk Lymphoma | 2021 |
| 33764809 | Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. | J Clin Oncol | 2021 |
| 33734005 | Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. | Leuk Lymphoma | 2021 |
| 33554406 | Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. | Oncologist | 2021 |
| 34529025 | Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. | JAMA Oncol | 2021 |
| 34525183 | Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. | Blood | 2021 |
| 34607348 | Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. | Blood Adv | 2021 |
| 33273183 | Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. | AIDS | 2021 |
| 33211080 | Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. | JAMA Oncol | 2021 |
| 31371656 | Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. | J Rheumatol | 2020 |
| 32202637 | Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. | Blood | 2020 |
| 32109194 | Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. | J Clin Oncol | 2020 |
| 32286905 | CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. | J Clin Oncol | 2020 |
| 32103145 | Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. | Leukemia | 2020 |
| 31665200 | Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. | Am J Clin Pathol | 2020 |
| 32040482 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia. | PLoS One | 2020 |
| 31981407 | Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement. | Pediatr Blood Cancer | 2020 |
| 32808680 | A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. | Am J Hematol | 2020 |
| 31371656 | Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. | J Rheumatol | 2020 |
| 31665200 | Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. | Am J Clin Pathol | 2020 |
| 31981407 | Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement. | Pediatr Blood Cancer | 2020 |
| 32040482 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia. | PLoS One | 2020 |
| 32103145 | Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. | Leukemia | 2020 |
| 32808680 | A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. | Am J Hematol | 2020 |
| 32109194 | Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. | J Clin Oncol | 2020 |
| 32202637 | Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. | Blood | 2020 |
| 32286905 | CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. | J Clin Oncol | 2020 |